看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -1.0x - -1.1x | -1.0x |
| Selected Fwd P/E Multiple | -1.4x - -1.6x | -1.5x |
| Fair Value | ¥0.70 - ¥0.77 | ¥0.73 |
| Upside | -7.1% - 2.7% | -2.2% |
| Benchmarks | - | Full Ticker |
| Sinotherapeutics Inc. | 68,824,700.0% | SHSE:688247 |
| HARBIN GLORIA PHARMACEUTICALS Co., LTD | 243,700.0% | SZSE:002437 |
| Tianjin Chase Sun Pharmaceutical Co.,Ltd | 30,002,600.0% | SZSE:300026 |
| Xiangxue Pharmaceutical Co.,Ltd. | 30,014,700.0% | SZSE:300147 |
| Shanghai Fudan Forward S&T Co., Ltd | 60,062,400.0% | SHSE:600624 |
| Ji Yao Holding Group Co., Ltd. | 30,010,800.0% | SZSE:300108 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| 688247 | 2437 | 300026 | 300147 | 600624 | 300108 | |||
| SHSE:688247 | SZSE:002437 | SZSE:300026 | SZSE:300147 | SHSE:600624 | SZSE:300108 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 94.2% | -0.9% | -33.8% | NM- | -32.6% | NM- | ||
| 3Y CAGR | -1.7% | -33.0% | -58.0% | NM- | NM- | NM- | ||
| Latest Twelve Months | 110.0% | 182.0% | -89.9% | -22.0% | -821.9% | -289.6% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 33.7% | -11.9% | 7.5% | -12.5% | -3.0% | -112.3% | ||
| Prior Fiscal Year | 20.4% | -9.4% | 8.3% | -24.2% | -0.8% | -56.4% | ||
| Latest Fiscal Year | 25.0% | 4.6% | 0.9% | -16.9% | 0.9% | -100.9% | ||
| Latest Twelve Months | 25.0% | 3.3% | 0.9% | -21.9% | -5.2% | -120.3% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 22.3x | 21.7x | 28.0x | 44.6x | 364.7x | -9.3x | ||
| Price / LTM Sales | 8.5x | 2.2x | 1.7x | 1.8x | 6.8x | 1.4x | ||
| LTM P/E Ratio | 33.9x | 67.9x | 196.5x | -8.1x | -130.7x | -1.1x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -130.7x | 33.9x | 196.5x | |||||
| Historical LTM P/E Ratio | -19.3x | -2.9x | 20.6x | |||||
| Selected P/E Multiple | -1.0x | -1.0x | -1.1x | |||||
| (x) LTM Net Income | (436) | (436) | (436) | |||||
| (=) Equity Value | 429 | 452 | 474 | |||||
| (/) Shares Outstanding | 666.0 | 666.0 | 666.0 | |||||
| Implied Value Range | 0.64 | 0.68 | 0.71 | |||||
| FX Rate: CNY/CNY | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.64 | 0.68 | 0.71 | 0.75 | ||||
| Upside / (Downside) | -14.1% | -9.5% | -5.0% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 688247 | 2437 | 300026 | 300147 | 600624 | 300108 | |
| Value of Common Equity | 4,342 | 5,449 | 10,034 | 3,710 | 4,334 | 500 | |
| (/) Shares Outstanding | 449.0 | 2,279.7 | 3,004.2 | 661.3 | 679.3 | 666.0 | |
| Implied Stock Price | 9.67 | 2.39 | 3.34 | 5.61 | 6.38 | 0.75 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 9.67 | 2.39 | 3.34 | 5.61 | 6.38 | 0.75 | |
| Trading Currency | CNY | CNY | CNY | CNY | CNY | CNY | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |